Key result
Levosimendan reduces ischemia/reperfusion injury and inhibits cardiomyocyte apoptosis across preclinical models.
Why the study?
Despite levosimendan's approval for cardiac failure, its superiority over β-adrenergic agonists for long-term survival is uncertain, and the link between its effects on ischemia/reperfusion injury and cardiomyocyte apoptosis is not well established.
Does levosimendan reduce ischemia/reperfusion injury and inhibit cardiomyocyte apoptosis?
Population
Patients or experimental models with ischemia/reperfusion injury and cardiomyocyte apoptosis
Comparison
Levosimendan effects vs other treatments or controls
Design
Review of experimental studies and clinical trials
Authors
Loading...
Should not yet change practice in ischemia/reperfusion injury; leaves open molecular mechanisms and requires prospective validation.
Does levosimendan reduce ischemia/reperfusion injury and inhibit cardiomyocyte apoptosis?
This review highlights the potential of levosimendan to reduce ischemia/reperfusion injury and inhibit cardiomyocyte apoptosis, extending its therapeutic relevance beyond positive inotropy in heart failure.
Scheiermann et al. (2011) conducted a review in Ischemia/reperfusion injury and apoptosis. Levosimendan was evaluated. Levosimendan demonstrates beneficial effects in ischemia/reperfusion injury and effectively inhibits cardiomyocyte apoptosis, although the underlying molecular mechanisms remain unclear.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: